Recap: Immunovant Q4 Earnings
Portfolio Pulse from Benzinga Insights
Immunovant (NASDAQ: IMVT) reported Q4 earnings with an EPS of $-0.46, missing estimates by 6.98%. Revenue was down $0 from the same period last year. Last quarter, the company missed EPS by $0.1, resulting in a 2.95% share price drop the next day.
May 22, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Immunovant's Q4 earnings missed estimates with an EPS of $-0.46, down 6.98% from expectations. Last quarter's miss resulted in a 2.95% share price drop.
Immunovant's Q4 earnings missed estimates by 6.98%, which is likely to negatively impact the stock price in the short term. The company's previous earnings miss resulted in a 2.95% share price drop the next day, indicating a pattern of negative market reaction to earnings misses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100